dostęp otwarty

Tom 1, Nr 4 (2016)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2017-02-21
Pobierz cytowanie

Standardy postępowania w przypadkach choroby nowotworowej u kobiety w ciąży Część I. Wiadomości ogólne: epidemiologia, diagnostyka, leczenie, poradnictwo genetyczne

Zespół ekspertów
Ginekologia i Perinatologia Praktyczna 2016;1(4):172-188.

dostęp otwarty

Tom 1, Nr 4 (2016)
Rekomendacje
Opublikowany online: 2017-02-21

Streszczenie

Brak

Streszczenie

Brak
Pobierz cytowanie

Słowa kluczowe

choroba nowotworowa, rak szyjki macicy

Informacje o artykule
Tytuł

Standardy postępowania w przypadkach choroby nowotworowej u kobiety w ciąży Część I. Wiadomości ogólne: epidemiologia, diagnostyka, leczenie, poradnictwo genetyczne

Czasopismo

Ginekologia i Perinatologia Praktyczna

Numer

Tom 1, Nr 4 (2016)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

172-188

Opublikowany online

2017-02-21

Wyświetlenia strony

1035

Wyświetlenia/pobrania artykułu

7078

Rekord bibliograficzny

Ginekologia i Perinatologia Praktyczna 2016;1(4):172-188.

Słowa kluczowe

choroba nowotworowa
rak szyjki macicy

Autorzy

Zespół ekspertów

Referencje (81)
  1. Fader AN, Alward EK, Niederhauser A, et al. Cervical dysplasia in pregnancy: a multi-institutional evaluation. Am J Obstet Gynecol. 2010; 203(2): 113.e1–113.e6.
  2. Hannigan E. Cervical Cancer in Pregnancy. Clinical Obstetrics and Gynecology. 1990; 33(4): 837–845.
  3. Dudan R, Yon J, Ford J, et al. Carcinoma of the cervix and pregnancy. Gynecologic Oncology. 1973; 1(4): 283–289.
  4. YOST N, SANTOSO J, MCINTIRE D, et al. Postpartum Regression Rates of Antepartum Cervical Intraepithelial Neoplasia II and III Lesions. Obset Gynecol. 1999; 93(3): 359–362.
  5. ACOG Practice Bulletin No. 99: Management of Abnormal Cervical Cytology and Histology. Obstet Gynecol. 2008; 112(6): 1419–1444.
  6. Rozporządzenie Ministra Zdrowia z dnia 20 września 2012r. W sprawie standardów postępowania medycznego przy udzielaniu świadczeń zdrowotnych z zakresu opieki okołoporodowej sprawowanej nad kobietą w okresie fizjologicznej ciąży, fizjologicznego porodu, połogu oraz opieki nad noworodkiem Dz N poz 1100.
  7. Orr JW, Barrett JM, Orr PF, et al. The efficacy and safety of the cytobrush during pregnancy. Gynecol Oncol. 1992; 44(3): 260–262.
  8. Stillson T, Knight AL, Elswick RK. The effectiveness and safety of two cervical cytologic techniques during pregnancy. J Fam Pract. 1997; 45(2): 159–163.
  9. Wright TC Jr, Massad S, Dunton CJ i wsp. 2006 Consensus guidelines for the managament of women with abnormal cervical concer screening test. Am. J. Obstet Gynecol 2007, 197, 346-55.
  10. Dunn TS, Bajaj JE, Stamm CA, et al. Management of the minimally abnormal papanicolaou smear in pregnancy. J Low Genit Tract Dis. 2001; 5(3): 133–137.
  11. Kohan S, Beckman EM, Bigelow B, et al. The role of colposcopy in the management of cervical intraepithelial neoplasia during pregnancy and postpartum. J Reprod Med. 1980; 25(5): 279–284.
  12. Nasierowska- Guttmejer A, Kędzie W, Wojtylak S, et al. Polish recommendations regarding diagnostics and treatment of cervical squamous intraepithelial lesions according to the CAP/ASCCP guidelines. Gin Pol. 2016; 87(9): 670–676.
  13. Fader AN, Alward EK, Niederhauser A, et al. Cervical dysplasia in pregnancy: a multi-institutional evaluation. Am J Obstet Gynecol. 2010; 203(2): 113.e1–113.e6.
  14. Van Calsteren K, Vergote I, Amant F. Cervical neoplasia during pregnancy: diagnosis, management and prognosis. Best Pract Res Clin Obstet Gynaecol. 2005; 19(4): 611–630.
  15. Economos K, Perez Veridiano N, Delke I, et al. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol. 1993; 81(6): 915–918.
  16. Muller CY, Smith HO. Cervical neoplasia complicating pregnancy. Obstet Gynecol Clin North Am. 2005; 32(4): 533–546.
  17. Mukhopadhyay A, Shinde A, Naik R. Ovarian cysts and cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016; 33: 58–72.
  18. Sherard GB, Hodson CA, Williams HJ, et al. Adnexal masses and pregnancy: a 12-year experience. Am J Obstet Gynecol. 2003; 189(2): 358–62; discussion 362.
  19. Balci O, Gezginc K, Karatayli R, et al. Management and outcomes of adnexal masses during pregnancy: a 6-year experience. J Obstet Gynaecol Res. 2008; 34(4): 524–528.
  20. Giuntoli RL, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol. 2006; 49(3): 492–505.
  21. Oehler MK, Wain GV, Brand A. Gynaecological malignancies in pregnancy: a review. Aust N Z J Obstet Gynaecol. 2003; 43(6): 414–420.
  22. Cavaco-Gomes J, Jorge Moreira C, Rocha A, et al. Investigation and Management of Adnexal Masses in Pregnancy. Scientifica (Cairo). 2016; 2016: 3012802.
  23. Zhao XY, Huang HF, Lian LJ, et al. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer. 2006; 16(1): 8–15.
  24. Blake EA, Kodama M, Yunokawa M, et al. Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol. 2015; 186: 97–105.
  25. Blake EA, Carter CM, Kashani BN, et al. Feto-maternal outcomes of pregnancy complicated by ovarian sex-cord stromal tumor: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol. 2014; 175: 1–7.
  26. Kodama M, Grubbs BH, Blake EA, et al. Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol. 2014; 181: 145–156.
  27. Morice P, Uzan C, Gouy S, et al. Gynaecological cancers in pregnancy. Lancet. 2012; 379(9815): 558–569.
  28. Marret H, Lhommé C, Lecuru F, et al. Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010; 149(1): 18–21.
  29. Sayar H, Lhomme C, Verschraegen CF. Malignant adnexal masses in pregnancy. Obstet Gynecol Clin North Am. 2005; 32(4): 569–593.
  30. Telischak NA, Yeh BM, Joe BN, et al. MRI of adnexal masses in pregnancy. AJR Am J Roentgenol. 2008; 191(2): 364–370.
  31. Birchard KR, Brown MA, Hyslop WB, et al. MRI of acute abdominal and pelvic pain in pregnant patients. AJR Am J Roentgenol. 2005; 184(2): 452–458.
  32. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005; 6(5): 328–333.
  33. Doll R, Wakeford R. Risk of childhood cancer from fetal irradiation. Br J Radiol. 1997; 70: 130–139.
  34. Morice P, Uzan C, Gouy S, et al. Gynaecological cancers in pregnancy. Lancet. 2012; 379(9815): 558–569.
  35. Aslam N, Ong C, Woelfer B, et al. Serum CA125 at 11-14 weeks of gestation in women with morphologically normal ovaries. BJOG. 2000; 107(5): 689–690.
  36. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci. 2007; 44(2): 151–178.
  37. Muyldermans M, Cornillie FJ, Koninckx PR. Hum Reprod Update. 1995; 1(2): 173–87.
  38. Han SN, Lotgerink A, Gziri MM, et al. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med. 2012; 10: 86.
  39. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6): 2162–2169.
  40. Moore RG, Miller MC, Eklund EE, et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012; 206(4): 349.e1–349.e7.
  41. Al Musalhi K, Al Kindi M, Al Aisary F, et al. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. Oman Med J. 2016; 31(5): 336–344.
  42. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108(2): 402–408.
  43. Aggarwal P, Kehoe S. Ovarian tumours in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol. 2011; 155(2): 119–124.
  44. Glanc P, Salem S, Farine D. Adnexal masses in the pregnant patient: a diagnostic and management challenge. Ultrasound Q. 2008; 24(4): 225–240.
  45. Fruscio R, de Haan J, Van Calsteren K, et al. Ovarian cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016 [Epub ahead of print].
  46. Amant F, Halaska MJ, Fumagalli M, et al. ESGO task force ‘Cancer in Pregnancy’. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014; 24(3): 394–403.
  47. Marret H, Lhommé C, Lecuru F, et al. Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010; 149(1): 18–21.
  48. Prat J. FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2014; 124(1): 1–5.
  49. Rubach M, Mądry R, Wełnicka-Jaśkiewicz M. Nowotwory w ciąży. In: Krzakowski M, Warzocha K. ed. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Medica, Gdańsk 2013.
  50. Amant F, Halaska MJ, Fumagalli M, et al. ESGO task force ‘Cancer in Pregnancy’. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer. 2009; 19 Suppl 1(3): S1–12.
  51. NCCN Guidelines Version 1.2016 Updates Ovarian Cancer.
  52. Grimm D, Woelber L, Trillsch F, et al. Clinical management of epithelial ovarian cancer during pregnancy. Eur J Cancer. 2014; 50(5): 963–971.
  53. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. Obstet Gynecol. 2011; 117(2 Pt 1): 420–421.
  54. Reginald PW, Beard RW, Chapple J, et al. Outcome of pregnancies progressing beyond 28 weeks gestation in women with a history of recurrent miscarriage. Br J Obstet Gynaecol. 1987; 94(7): 643–648.
  55. Bates SM, Greer IA, Pabinger I, et al. American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl): 844S–886S.
  56. Ebert U, Löffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997; 74(2): 207–220.
  57. Smith ER, Borowsky ME, Jain VD. Intraperitoneal chemotherapy in a pregnant woman with ovarian cancer. Obstet Gynecol. 2013; 122(2 Pt 2): 481–483.
  58. Chudecka-Głaz A. Nowotwory germinalne jajnika. In: Markowska J, Mądry J. ed. Zarys ginekologii onkologicznej. Termedia, Poznań 2012.
  59. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994; 12(4): 701–706.
  60. Skrzypczyk-Ostaszewicz A, Rubach M. Gynaecological cancers coexisting with pregnancy - a literature review. Contemp Oncol (Pozn). 2016; 20(3): 193–198.
  61. Ngu SF, Ngan HYS. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016; 33: 86–101.
  62. Van Calsteren K, Verbesselt R, Ottevanger N, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010; 89(10): 1338–1345.
  63. Lambertini M, Kamal NS, Peccatori FA, et al. Exploring the safety of chemotherapy for treating breast cancer during pregnancy. Expert Opin Drug Saf. 2015; 14(9): 1395–1408.
  64. Kakoulidis I, Skagias L, Politi E. Pregnancy associated breast cancer (PABC): aspects in diagnosis. Breast Dis. 2015; 35(3): 157–166.
  65. Jeziorski A, Nowecki ZI. Chirurgiczne leczenie zmian nowotworowych piersi – Konsensus Polskiego Towarzystwa Chirurgii Onkologicznej pod patronatem merytorycznym Konsultanta Krajowego w dziedzinie Chirurgii Onkologicznej. Via Medica , Gdańsk 2016.
  66. Ray JG, Vermeulen MJ, Bharatha A, et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA. 2016; 316(9): 952–961.
  67. American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee Opinion No. 656: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol. 2016; 127(2): e75–e80.
  68. Cardonick E. Pregnancy-associated breast cancer: optimal treatment options. Int J Womens Health. 2014; 6: 935–943.
  69. Toesca A, Gentilini O, Peccatori F, et al. Locoregional treatment of breast cancer during pregnancy. Gynecol Surg. 2014; 11(4): 279–284.
  70. Caragacianu DL, Mayer EL, Chun YS, et al. Immediate breast reconstruction following mastectomy in pregnant women with breast cancer. J Surg Oncol. 2016; 114(2): 140–143.
  71. Lohsiriwat V, Peccatori FA, Martella S, et al. Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast. 2013; 22(5): 657–660.
  72. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015; 1(8): 1145–1153.
  73. Loibl S, Han SN, Amant F. Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel). 2012; 7(3): 204–209.
  74. Amant F, Loibl S, Neven P, et al. Breast cancer in pregnancy. The Lancet. 2012; 379(9815): 570–579.
  75. Amant F, Halaska MJ, Fumagalli M, et al. ESGO task force ‘Cancer in Pregnancy’. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010; 46(18): 3158–3168.
  76. Loibl S. Adjuvant therapy in patients with breast cancer during pregnancy. Cancer Treat Res. 2009; 151: 317–328.
  77. Skrzypczyk-Ostaszewicz A, et al. Rak piersi współistniejący z ciążą. Curr Gynecol Oncol. 2014; 12(1).
  78. Calsteren KV, Verbesselt R, Devlieger R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer. 2010; 20(9): 1456–1464.
  79. Lambertini M, Peccatori FA, Azim HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015; 41(4): 301–309.
  80. El-Safadi S, Wuesten O, Muenstedt K. Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res. 2012; 38(3): 589–592.
  81. Peccatori FA, Azim HA, Orecchia R, et al. ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi160–vi170.

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl